Mechanisms of physiological and pathological cardiac hypertrophy

Nature Reviews Cardiology

Volumn 15, Issue 7, 2018, Pages 387-407

  Nakamura, Michinari ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BETA1 INTEGRIN; CALCINEURIN; CATECHOLAMINE; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOCHONDRIAL PROTEIN; NATRIURETIC FACTOR; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PROTEIN MELUSIN; SOMATOMEDIN C; STROMAL INTERACTION MOLECULE 1; THYROID HORMONE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANGIOGENESIS; CAPILLARY DENSITY; CARDIAC MUSCLE CELL; CELL PROLIFERATION; DISEASE ACTIVITY; DNA MODIFICATION; DRUG TARGETING; EPIGENETICS; FRUCTOSE METABOLISM; GENE; GENE EXPRESSION; GENE MUTATION; GLUCOSE METABOLISM; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE HYPERTROPHY; HIPPO SIGNALING; HUMAN; IMMUNOCOMPETENT CELL; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; MTOR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN RNA BINDING; REGENERATIVE MEDICINE; REVIEW; TREATMENT OUTCOME; VEGFA GENE; ADAPTATION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; ENERGY METABOLISM; EXERCISE INDUCED CARDIOMEGALY; HEART MITOCHONDRION; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CARDIOMEGALY; CARDIOMEGALY, EXERCISE-INDUCED; ENERGY METABOLISM; HEART VENTRICLES; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; REGENERATION; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 85045747976     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/s41569-018-0007-y     Document Type: Review

References (318)

1. Braunwald, E. Heart failure. JACC Heart Fail. 1, 1-20 (2013).
2. Schiattarella, G. G. & Hill, J. A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131, 1435-1447 (2015).
3. Redfield, M. M. Heart failure with preserved ejection fraction. N. Engl. J. Med. 375, 1868-1877 (2016).
4. Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14, 591-602 (2017).
5. Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131, 550-559 (2015).
6. Maillet, M., van Berlo, J. H. & Molkentin, J. D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 14, 38-48 (2013).
7. van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 123, 37-45 (2013).
8. Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128, 191-227 (2010).
9. Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89, 1401-1438 (2015).
10. Shimizu, I. & Minamino, T. Physiological and pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 97, 245-262 (2016).
11. Perrino, C. et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560 (2006).
12. Vega, R. B., Konhilas, J. P., Kelly, D. P. & Leinwand, L. A. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 25, 1012-1026 (2017).
13. McMullen, J. R. et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104, 612-617 (2007).
14. Tsujita, Y. et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl Acad. Sci. USA 103, 11946-11951 (2006).
15. Turkbey, E. B. et al. The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc. Imaging 3, 266-274 (2010).
16. Devereux, R. B. et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101, 2271-2276 (2000).
17. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001).
18. Neri Serneri, G. G. et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 89, 977-982 (2001).
19. Olszanecka, A., Dragan, A., Kawecka-Jaszcz, K., Fedak, D. & Czarnecka, D. Relationships of insulin-like growth factor-1, its binding proteins, and cardiometabolic risk in hypertensive perimenopausal women. Metabolism 69, 96-106 (2017).
20. Riehle, C. et al. Insulin receptor substrates are essential for the bioenergetic and hypertrophic response of the heart to exercise training. Mol. Cell. Biol. 34, 3450-3460 (2014).
21. Kim, J. et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 22, 2531-2543 (2008).
22. McMullen, J. R. et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 279, 4782-4793 (2004).
23. Troncoso, R., Ibarra, C., Vicencio, J. M., Jaimovich, E. & Lavandero, S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 25, 128-137 (2014).
24. McMullen, J. R. et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 12355-12360 (2003).
25. Weeks, K. L. et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5, 523-534 (2012).
26. DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097-2104 (2006).
27. Skurk, C. et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280, 20814-20823 (2005).
28. O'Neill, B. T. et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 6, 294-306 (2007).
29. Bueno, O. F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341-6350 (2000).
30. Bostrom, P. et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072-1083 (2010).
31. Bezzerides, V. J. et al. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. JCI Insight 1, e85904 (2016).
32. Pantos, C., Mourouzis, I. & Cokkinos, D. V. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail. Rev. 16, 79-96 (2011).
33. Fisher, D. A. & Klein, A. H. Thyroid development and disorders of thyroid function in the newborn. N. Engl. J. Med. 304, 702-712 (1981).
34. Morkin, E. Control of cardiac myosin heavy chain gene expression. Microsc. Res. Tech. 50, 522-531 (2000).
35. 2+-ATPase and alpha-myosin heavy chain in rat hearts. J. Clin. Invest. 100, 1742-1749 (1997).
36. Pantos, C. et al. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J. Physiol. Pharmacol. 60, 49-56 (2009).
37. Trivieri, M. G. et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc. Natl Acad. Sci. USA 103, 6043-6048 (2006).
38. Belke, D. D., Gloss, B., Swanson, E. A. & Dillmann, W. H. Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148, 2870-2877 (2007).
39. Calvert, J. W. et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ. Res. 108, 1448-1458 (2011).
40. Huang, P. L. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242 (1995).
41. Lee, P. C. et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 277, H1600-H1608 (1999).
42. Li, W. et al. Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. J. Mol. Cell. Cardiol. 37, 671-680 (2004).
43. Rainer, P. P. & Kass, D. A. Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. Cardiovasc. Res. 111, 154-162 (2016).
44. Tamirisa, P., Blumer, K. J. & Muslin, A. J. RGS4 inhibits G-protein signaling in cardiomyocytes. Circulation 99, 441-447 (1999).
45. Rogers, J. H. et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104, 567-576 (1999).
46. Takimoto, E. et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119, 408-420 (2009).
47. de Waard, M. C. et al. Beneficial effects of exercise training after myocardial infarction require full eNOS expression. J. Mol. Cell. Cardiol. 48, 1041-1049 (2010).
48. Oka, T., Akazawa, H., Naito, A. T. & Komuro, I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114, 565-571 (2014).
49. Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495-502 (1999).
50. Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457-1467 (2016).
51. Hudlicka, O., Brown, M. & Egginton, S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 72, 369-417 (1992).
52. Hamasaki, S. et al. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J. Am. Coll. Cardiol. 35, 1654-1660 (2000).
53. Togni, M. et al. Instantaneous coronary collateral function during supine bicycle exercise. Eur. Heart J. 31, 2148-2155 (2010).
54. Mobius-Winkler, S. et al. Coronary collateral growth induced by physical exercise: results of the impact of intensive exercise training on coronary collateral circulation in patients with stable coronary artery disease (EXCITE) Trial. Circulation 133, 1438-1448 (2016).
55. Elkayam, U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J. Am. Coll. Cardiol. 58, 659-670 (2011).
56. Patten, I. S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333-338 (2012).
57. Goland, S. et al. Angiogenic imbalance and residual myocardial injury in recovered peripartum cardiomyopathy patients. Circ. Heart Fail. 9, e003349 (2016).
58. Damp, J. et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail. 4, 380-388 (2016).
59. Semenza, G. L. Hypoxia-inducible factor 1 and cardiovascular disease. Annu. Rev. Physiol. 76, 39-56 (2014).
60. Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108-2118 (2005).
61. Shiojima, I. & Walsh, K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 20, 3347-3365 (2006).
62. Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47, 887-893 (2006).
63. Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444-448 (2007).
64. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44 (2000).
65. Heineke, J. et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 117, 3198-3210 (2007).
66. Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451, 1008-1012 (2008).
67. Torry, R. J. et al. Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J. Heart Lung Transplant 28, 183-190 (2009).
68. Accornero, F. et al. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ. Res. 109, 272-280 (2011).
69. Shindo, T. et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856-863 (2002).
70. Chintalgattu, V. et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472-484 (2010).
71. Tromp, J. et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J. Am. Heart Assoc. 6, e003989 (2017).
72. Odiete, O., Hill, M. F. & Sawyer, D. B. Neuregulin in cardiovascular development and disease. Circ. Res. 111, 1376-1385 (2012).
73. Hirai, M. et al. Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J. Clin. Invest. 127, 569-582 (2017).
74. Waring, C. D. et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur. Heart J. 35, 2722-2731 (2014).
75. Fukazawa, R. et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol. 35, 1473-1479 (2003).
76. Bersell, K., Arab, S., Haring, B. & Kuhn, B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257-270 (2009).
77. D'Uva, G. et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627-638 (2015).
78. Gemberling, M., Karra, R., Dickson, A. L. & Poss, K. D. Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. eLIFE 4, e05871 (2015).
79. Polizzotti, B. D. et al. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci. Transl. Med. 7, 281ra45 (2015).
80. Lyon, R. C., Zanella, F., Omens, J. H. & Sheikh, F. Mechanotransduction in cardiac hypertrophy and failure. Circ. Res. 116, 1462-1476 (2015).
81. De Acetis, M. et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ. Res. 96, 1087-1094 (2005).
82. Brancaccio, M. et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9, 68-75 (2003).
83. Fernandes, T., Barauna, V. G., Negrao, C. E., Phillips, M. I. & Oliveira, E. M. Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs. Am. J. Physiol. Heart Circ. Physiol. 309, H543-H552 (2015).
84. Liu, X. et al. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 21, 584-595 (2015).
85. Chorghade, S. et al. Poly(A) tail length regulates PABPC1 expression to tune translation in the heart. eLIFE 6, e24139 (2017).
86. Zhang, L. et al. Phospholipase cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell 153, 216-227 (2013).
87. Newton, A. C., Antal, C. E. & Steinberg, S. F. Protein kinase C mechanisms that contribute to cardiac remodelling. Clin. Sci. 130, 1499-1510 (2016).
88. Braz, J. C. et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248-254 (2004).
89. Kadambi, V. J. et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533-539 (1996).
90. Luo, W. et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75, 401-409 (1994).
91. 2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230-1240 (2009).
92. Backs, J. et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc. Natl Acad. Sci. USA 106, 2342-2347 (2009).
93. Ago, T. et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978-993 (2008).
94. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
95. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42 (2009).
96. Gallo, P. et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80, 416-424 (2008).
97. Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228 (1998).
98. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110-118 (2004).
99. Rose, B. A., Force, T. & Wang, Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90, 1507-1546 (2010).
100. Lymperopoulos, A., Rengo, G. & Koch, W. J. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739-753 (2013).
101. Sato, P. Y., Chuprun, J. K., Schwartz, M. & Koch, W. J. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol. Rev. 95, 377-404 (2015).
102. Woodall, M. C., Ciccarelli, M., Woodall, B. P. & Koch, W. J. G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ. Res. 114, 1661-1670 (2014).
103. Schumacher, S. M. & Koch, W. J. Noncanonical roles of G Protein-coupled receptor kinases in cardiovascular signaling. J. Cardiovasc. Pharmacol. 70, 129-141 (2017).
104. Martini, J. S. et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl Acad. Sci. USA 105, 12457-12462 (2008).
105. Hullmann, J. E. et al. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ. Res. 115, 976-985 (2014).
106. Traynham, C. J. et al. Differential role of G protein-coupled receptor kinase 5 in physiological versus pathological cardiac hypertrophy. Circ. Res. 117, 1001-1012 (2015).
107. Gold, J. I., Gao, E., Shang, X., Premont, R. T. & Koch, W. J. Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ. Res. 111, 1048-1053 (2012).
108. Morel, E. et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ. Res. 97, 1296-1304 (2005).
109. Metrich, M. et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ. Res. 102, 959-965 (2008).
110. 2+ leak and arrhythmia. Circulation 127, 913-922 (2013).
111. Okumura, S. et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J. Clin. Invest. 124, 2785-2801 (2014).
112. Pereira, L. et al. Novel Epac fluorescent ligand reveals distinct Epac1 versus Epac2 distribution and function in cardiomyocytes. Proc. Natl Acad. Sci. USA 112, 3991-3996 (2015).
113. Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960-976 (2017).
114. Sciarretta, S., Forte, M., Frati, G. & Sadoshima, J. New insights into the role of mTOR signaling in the cardiovascular system. Circ. Res. 122, 489-505 (2018).
115. Zhang, D. et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 120, 2805-2816 (2010).
116. Sadoshima, J. & Izumo, S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ. Res. 77, 1040-1052 (1995).
117. Shioi, T. et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664-1670 (2003).
118. McMullen, J. R. et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 24, 6231-6240 (2004).
119. Sciarretta, S. et al. mTORC2 regulates cardiac response to stress by inhibiting MST1. Cell Rep. 11, 125-136 (2015).
120. Holtwick, R. et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest. 111, 1399-1407 (2003).
121. Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11, 214-222 (2005).
122. Lee, D. I. et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519, 472-476 (2015).
123. Pinto, A. R. et al. Revisiting cardiac cellular composition. Circ. Res. 118, 400-409 (2016).
124. Leask, A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ. Res. 116, 1269-1276 (2015).
125. Kakkar, R. & Lee, R. T. Intramyocardial fibroblast myocyte communication. Circ. Res. 106, 47-57 (2010).
126. Pellieux, C. et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 108, 1843-1851 (2001).
127. Schultz, J. E. et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J. Clin. Invest. 104, 709-719 (1999).
128. Kuwahara, F. et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106, 130-135 (2002).
129. Divakaran, V. et al. Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ. Heart Fail. 2, 633-642 (2009).
130. Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6, 556-563 (2000).
131. Koitabashi, N. et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301-2312 (2011).
132. Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110-115 (2017).
133. Takeda, N. et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-265 (2010).
134. Bang, C. et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 124, 2136-2146 (2014).
135. Frieler, R. A. & Mortensen, R. M. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131, 1019-1030 (2015).
136. Testa, M. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 28, 964-971 (1996).
137. Melendez, G. C. et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225-231 (2010).
138. Hirota, H., Yoshida, K., Kishimoto, T. & Taga, T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl Acad. Sci. USA 92, 4862-4866 (1995).
139. Zhao, L. et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ. Res. 118, 1918-1929 (2016).
140. Hirota, H. et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189-198 (1999).
141. Kubota, T. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81, 627-635 (1997).
142. Sun, M. et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115, 1398-1407 (2007).
143. Nishikawa, K. et al. Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am. J. Physiol. Heart Circ. Physiol. 291, H176-H183 (2006).
144. Honsho, S. et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ. Res. 105, 1149-1158 (2009).
145. Van Tassell, B. W. et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am. J. Cardiol. 113, 321-327 (2014).
146. Van Tassell, B. W. et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ. Heart Fail. 10, e004373 (2017).
147. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119-1131 (2017).
148. Verma, S. K. et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 126, 418-429 (2012).
149. Sobirin, M. A. et al. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ. Res. 111, 1037-1047 (2012).
150. Kallikourdis, M. et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat. Commun. 8, 14680 (2017).
151. Tirziu, D., Giordano, F. J. & Simons, M. Cell communications in the heart. Circulation 122, 928-937 (2010).
152. Chen, W. Y., Hong, J., Gannon, J., Kakkar, R. & Lee, R. T. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc. Natl Acad. Sci. USA 112, 7249-7254 (2015).
153. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007).
154. Appari, M. et al. C1q-TNF-related protein-9 promotes cardiac hypertrophy and failure. Circ. Res. 120, 66-77 (2017).
155. Sun, Y. et al. C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 128, S113-S120 (2013).
156. Eder, P. & Molkentin, J. D. TRPC channels as effectors of cardiac hypertrophy. Circ. Res. 108, 265-272 (2011).
157. Kuwahara, K. et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 116, 3114-3126 (2006).
158. Onohara, N. et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 25, 5305-5316 (2006).
159. Bush, E. W. et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 281, 33487-33496 (2006).
160. Seo, K. et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc. Natl Acad. Sci. USA 111, 1551-1556 (2014).
161. Takahashi, S. et al. Nitric oxide-cGMP-protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6. J. Physiol. 586, 4209-4223 (2008).
162. Wu, X., Eder, P., Chang, B. & Molkentin, J. D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl Acad. Sci. USA 107, 7000-7005 (2010).
163. Makarewich, C. A. et al. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ. Res. 115, 567-580 (2014).
164. Correll, R. N. et al. STIM1 elevation in the heart results in aberrant Ca(2)(+) handling and cardiomyopathy. J. Mol. Cell. Cardiol. 87, 38-47 (2015).
165. Troupes, C. D. et al. Role of STIM1 (stromal interaction molecule 1) in hypertrophy-related contractile dysfunction. Circ. Res. 121, 125-136 (2017).
166. Luo, X. et al. STIM1-dependent store-operated Ca(2)(+) entry is required for pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 52, 136-147 (2012).
167. Benard, L. et al. Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling. Circulation 133, 1458-1471 (2016).
168. Burke, M. A., Cook, S. A., Seidman, J. G. & Seidman, C. E. Clinical and mechanistic insights into the genetics of cardiomyopathy. J. Am. Coll. Cardiol. 68, 2871-2886 (2016).
169. Marian, A. J. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749-770 (2017).
170. Davis, J. et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy. Cell 165, 1147-1159 (2016).
171. Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest. 120, 3520-3529 (2010).
172. Papait, R. et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc. Natl Acad. Sci. USA 110, 20164-20169 (2013).
173. Zhang, Q. J. et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Invest. 121, 2447-2456 (2011).
174. Thienpont, B. et al. The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy. J. Clin. Invest. 127, 335-348 (2017).
175. Han, P. et al. Epigenetic response to environmental stress: assembly of BRG1-G9a/GLP-DNMT3 repressive chromatin complex on Myh6 promoter in pathologically stressed hearts. Biochim. Biophys. Acta 1863, 1772-1781 (2016).
176. Papait, R. et al. Histone methyltransferase G9a is required for cardiomyocyte homeostasis and hypertrophy. Circulation 136, 1233-1246 (2017).
177. Wang, Z. et al. The long noncoding RNA chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat. Med. 22, 1131-1139 (2016).
178. Fatica, A. & Bozzoni, I. Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15, 7-21 (2014).
179. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155-159 (2009).
180. Batista, P. J. & Chang, H. Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 152, 1298-1307 (2013).
181. Harada, M. et al. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ. Res. 114, 689-705 (2014).
182. Marks, A. R. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46-52 (2013).
183. Meguro, T. et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84, 735-740 (1999).
184. Maillet, M. et al. Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J. Biol. Chem. 285, 6716-6724 (2010).
185. Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M. & Mueller, F. O. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 119, 1085-1092 (2009).
186. Maron, B. J. Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br. J. Sports Med. 43, 649-656 (2009).
187. Shimizu, I. et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120, 1506-1514 (2010).
188. Strom, C. C. et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J. 272, 2684-2695 (2005).
189. Zhang, L. et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail. 6, 1039-1048 (2013).
190. Liew, C. W. et al. Multiphasic regulation of systemic and peripheral organ metabolic responses to cardiac hypertrophy. Circ. Heart Fail. 10, e003864 (2017).
191. Doenst, T., Nguyen, T. D. & Abel, E. D. Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 113, 709-724 (2013).
192. Neubauer, S. The failing heart - an engine out of fuel. N. Engl. J. Med. 356, 1140-1151 (2007).
193. Huss, J. M. et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 6, 25-37 (2007).
194. Sung, M. M. et al. Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure. Am. J. Physiol. Heart Circ. Physiol. 312, H552-H560 (2017).
195. Boudina, S. et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119, 1272-1283 (2009).
196. Chiu, H. C. et al. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107, 813-822 (2001).
197. Finck, B. N. et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121-130 (2002).
198. Yagyu, H. et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Invest. 111, 419-426 (2003).
199. Chiu, H. C. et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96, 225-233 (2005).
200. Son, N. H. et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791-2801 (2007).
201. Cheng, L. et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245-1250 (2004).
202. Lai, L. et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ. Heart Fail. 7, 1022-1031 (2014).
203. Vega, R. B., Horton, J. L. & Kelly, D. P. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ. Res. 116, 1820-1834 (2015).
204. Aubert, G., Vega, R. B. & Kelly, D. P. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim. Biophys. Acta 1833, 840-847 (2013).
205. Doenst, T. et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc. Res. 86, 461-470 (2010).
206. Razeghi, P. et al. Metabolic gene expression in fetal and failing human heart. Circulation 104, 2923-2931 (2001).
207. Kolwicz, S. C. Jr et al. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 111, 728-738 (2012).
208. Choi, Y. S. et al. Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. J. Mol. Cell. Cardiol. 100, 64-71 (2016).
209. Burelle, Y. et al. Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 287, H1055-H1063 (2004).
210. Burkart, E. M. et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117, 3930-3939 (2007).
211. Huss, J. M., Torra, I. P., Staels, B., Giguere, V. & Kelly, D. P. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24, 9079-9091 (2004).
212. Fan, W. & Evans, R. PPARs and ERRs: molecular mediators of mitochondrial metabolism. Curr. Opin. Cell Biol. 33, 49-54 (2015).
213. Rowe, G. C., Jiang, A. & Arany, Z. PGC-1 coactivators in cardiac development and disease. Circ. Res. 107, 825-838 (2010).
214. Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J. & Kelly, D. P. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723-1730 (2000).
215. Fan, W. & Evans, R. M. Exercise mimetics: impact on health and performance. Cell Metab. 25, 242-247 (2017).
216. Jager, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl Acad. Sci. USA 104, 12017-12022 (2007).
217. Narkar, V. A. et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405-415 (2008).
218. Vettor, R. et al. Exercise training boosts eNOS-dependent mitochondrial biogenesis in mouse heart: role in adaptation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 306, E519-E528 (2014).
219. Boudina, S. & Abel, E. D. Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223 (2007).
220. Schilling, J. D. & Mann, D. L. Diabetic cardiomyopathy: bench to bedside. Heart Fail. Clin. 8, 619-631 (2012).
221. Szczepaniak, L. S., Victor, R. G., Orci, L. & Unger, R. H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 101, 759-767 (2007).
222. Rijzewijk, L. J. et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J. Am. Coll. Cardiol. 54, 1524-1532 (2009).
223. Rijzewijk, L. J. et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52, 1793-1799 (2008).
224. Goldberg, I. J., Trent, C. M. & Schulze, P. C. Lipid metabolism and toxicity in the heart. Cell Metab. 15, 805-812 (2012).
225. Wang, G. et al. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem. 280, 26415-26424 (2005).
226. Koves, T. R. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45-56 (2008).
227. Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121, 4222-4230 (2011).
228. Chavez, J. A. & Summers, S. A. A ceramide-centric view of insulin resistance. Cell Metab. 15, 585-594 (2012).
229. Park, T. S. et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49, 2101-2112 (2008).
230. Russo, S. B. et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 122, 3919-3930 (2012).
231. Son, N. H. et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120, 3443-3454 (2010).
232. Ji, R. et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight 2, e82922 (2017).
233. Reforgiato, M. R. et al. Inhibition of ceramide de novo synthesis as a postischemic strategy to reduce myocardial reperfusion injury. Basic Res. Cardiol. 111, 12 (2016).
234. Zhang, Y. et al. Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload. JCI Insight 1, e85484 (2016).
235. Lee, S. Y. et al. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J. Biol. Chem. 287, 18429-18439 (2012).
236. Schooneman, M. G., Vaz, F. M., Houten, S. M. & Soeters, M. R. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62, 1-8 (2013).
237. Bedi, K. C. Jr et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133, 706-716 (2016).
238. Sansbury, B. E. et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ. Heart Fail. 7, 634-642 (2014).
239. Ahmad, T. et al. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 67, 291-299 (2016).
240. Geraldes, P. & King, G. L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106, 1319-1331 (2010).
241. Jornayvaz, F. R. & Shulman, G. I. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15, 574-584 (2012).
242. Chokshi, A. et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125, 2844-2853 (2012).
243. Liu, L. et al. Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. J. Biol. Chem. 289, 29881-29891 (2014).
244. Newgard, C. B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 15, 606-614 (2012).
245. Jang, C. et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat. Med. 22, 421-426 (2016).
246. Sun, H. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133, 2038-2049 (2016).
247. Shao, D. & Tian, R. Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6, 331-351 (2015).
248. Sen, S. et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J. Am. Heart Assoc. 2, e004796 (2013).
249. Sharma, S., Guthrie, P. H., Chan, S. S., Haq, S. & Taegtmeyer, H. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc. Res. 76, 71-80 (2007).
250. Ritterhoff, J. & Tian, R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc. Res. 113, 411-421 (2017).
251. Ussher, J. R., Jaswal, J. S. & Lopaschuk, G. D. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ. Res. 111, 628-641 (2012).
252. Mirtschink, P. et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 522, 444-449 (2015).
253. Cotter, D. G., Schugar, R. C. & Crawford, P. A. Ketone body metabolism and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 304, H1060-H1076 (2013).
254. Lopaschuk, G. D. Metabolic modulators in heart disease: past, present, and future. Can. J. Cardiol. 33, 838-849 (2017).
255. Lommi, J. et al. Blood ketone bodies in congestive heart failure. J. Am. Coll. Cardiol. 28, 665-672 (1996).
256. Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698-705 (2016).
257. Schugar, R. C. et al. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol. Metab. 3, 754-769 (2014).
258. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
259. Lopaschuk, G. D. & Verma, S. Empagliflozin's fuel hypothesis: not so soon. Cell Metab. 24, 200-202 (2016).
260. Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190-1195 (2016).
261. Shimazu, T. et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211-214 (2013).
262. Taegtmeyer, H., Hems, R. & Krebs, H. A. Utilization of energy-providing substrates in the isolated working rat heart. Biochem. J. 186, 701-711 (1980).
263. Horton, J. L. et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight 1, e84897 (2016).
264. Nakamura, M. & Sadoshima, J. Heart over mind: metabolic control of white adipose tissue and liver. EMBO Mol. Med. 6, 1521-1524 (2014).
265. Shimano, M., Ouchi, N. & Walsh, K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation 126, e327-e332 (2012).
266. de Bold, A. J. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can. J. Physiol. Pharmacol. 89, 527-531 (2011).
267. Grueter, C. E. et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149, 671-683 (2012).
268. Baskin, K. K. et al. MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Mol. Med. 6, 1610-1621 (2014).
269. Fuster, J. J., Ouchi, N., Gokce, N. & Walsh, K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ. Res. 118, 1786-1807 (2016).
270. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97 (2011).
271. Shibata, R. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384-1389 (2004).
272. Fang, X. et al. Adipocyte-specific loss of PPARgamma attenuates cardiac hypertrophy. JCI Insight 1, e89908 (2016).
273. Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262 (2012).
274. Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016-1023 (2011).
275. Tian, R., Musi, N., D'Agostino, J., Hirshman, M. F. & Goodyear, L. J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104, 1664-1669 (2001).
276. Shao, D. et al. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. Cell Metab. 19, 232-245 (2014).
277. Kim, T. T. & Dyck, J. R. Is AMPK the savior of the failing heart? Trends Endocrinol. Metab. 26, 40-48 (2015).
278. Lee, C. F. et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation 134, 883-894 (2016).
279. Nakamura, M., Bhatnagar, A. & Sadoshima, J. Overview of pyridine nucleotides review series. Circ. Res. 111, 604-610 (2012).
280. Koentges, C., Bode, C. & Bugger, H. SIRT3 in cardiac physiology and disease. Front. Cardiovasc. Med. 3, 38 (2016).
281. Sundaresan, N. R. et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119, 2758-2771 (2009).
282. Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat. Commun. 6, 6656 (2015).
283. Zhang, R. et al. Short-term administration of nicotinamide mononucleotide preserves cardiac mitochondrial homeostasis and prevents heart failure. J. Mol. Cell. Cardiol. 112, 64-73 (2017).
284. Martin, A. S. et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model. JCI Insight 2, 93885 (2017).
285. Sundaresan, N. R. et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 18, 1643-1650 (2012).
286. Tang, X. et al. SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation 136, 2051-2067 (2017).
287. Alcendor, R. R. et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100, 1512-1521 (2007).
288. Oka, S. et al. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab. 14, 598-611 (2011).
289. Luo, Y. X. et al. SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur. Heart J. 38, 1389-1398 (2017).
290. Tzahor, E. & Poss, K. D. Cardiac regeneration strategies: staying young at heart. Science 356, 1035-1039 (2017).
291. Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680-686 (2017).
292. Cai, M. X. et al. Exercise training activates neuregulin 1/ErbB signaling and promotes cardiac repair in a rat myocardial infarction model. Life Sci. 149, 1-9 (2016).
293. Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility inp27(Kip1)-deficient mice. Cell 85, 733-744 (1996).
294. Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function ofp27(Kip1). Cell 85, 721-732 (1996).
295. Nakayama, K. et al. Mice lackingp27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
296. Hauck, L. et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat. Med. 14, 315-324 (2008).
297. Matsuda, T. et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl Acad. Sci. USA 105, 20900-20905 (2008).
298. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505 (2010).
299. Yu, F. X., Zhao, B. & Guan, K. L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811-828 (2015).
300. Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111, 1463-1474 (2003).
301. Heallen, T. et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458-461 (2011).
302. Maejima, Y. et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat. Med. 19, 1478-1488 (2013).
303. Del, Re,D. P. et al. Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. Mol. Cell 54, 639-650 (2014).
304. Nakamura, M., Zhai, P., Del Re, D. P., Maejima, Y. & Sadoshima, J. Mst1-mediated phosphorylation of Bcl-xL is required for myocardial reperfusion injury. JCI Insight 1, e86217 (2016).
305. Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of YAP. Cell 122, 421-434 (2005).
306. von Gise, A. et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl Acad. Sci. USA 109, 2394-2399 (2012).
307. Del Re, D. P. et al. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J. Biol. Chem. 288, 3977-3988 (2013).
308. Wang, P. et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. Basic Res. Cardiol. 109, 435 (2014).
309. Xin, M. et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci. Signal 4, ra70 (2011).
310. Xin, M. et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl Acad. Sci. USA 110, 13839-13844 (2013).
311. Lin, Z. et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res. 115, 354-363 (2014).
312. Li, J. et al. Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ. Res. 116, 70-79 (2015).
313. Morikawa, Y., Heallen, T., Leach, J., Xiao, Y. & Martin, J. F. Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547, 227-231 (2017).
314. Leach, J. P. et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature 550, 260-264 (2017).
315. Mo, J. S. et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17, 500-510 (2015).
316. Wang, W. et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17, 490-499 (2015).
317. DeRan, M. et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 9, 495-503 (2014).
318. Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. https://doi.org/10.1038/nrd.2017.229 (2018).